ArticleJournal of medical case reports2026
Metformin-induced xerostomia and chapped lips in a 56-year-old patient with early-stage diabetes: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundDiabetes mellitus is a common metabolic disorder. To date, over 589 million adults (1 in 9 people) have been diagnosed with diabetes, and over 3.4 million deaths have occurred annually due to diabetes mellitus. Therefore, early diagnosis and management of diabetes are essential to avoid its microvascular and macrovascular complications. Metformin, an oral biguianide, is considered as a first-line oral antidiabetic agent for patients diagnosed with either prediabetes or diabetes. CASE PRESENTATION: A 56-year-old Iranian male with early-stage diabetes was presented with xerostomia immediately after the first dose of metformin and continued with daily metformin consumption. Metformin-associated xerostomia have not been reported and documented to date. One of the possible causes of metformin-induced xerostomia would be adenosine monophosphate-activated protein kinase overactivation, which may cause reduced saliva production. In addition, mammalian target of rapamycin inhibition may lead to suppression of the salivary gland protein synthesis. Furthermore, metformin-induced Ca
conclusionsXerostomia and chapped lips are potential adverse drug reactions following metformin administration. Since metformin is a first-line oral antidiabetic agent that is commonly administered to a majority of patients with prediabetes or type 2 diabetes, it is crucial to closely monitor the patients and warn them about these potential adverse reactions for early diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.